Day: October 17, 2025

BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the pricing of its underwritten public offering of 3,025,480 shares of its common stock at a public offering price per share of $157.00 and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 318,470 shares of common stock at a purchase price of $156.9999 per pre-funded warrant, which equals the public offering price per share of the common stock less the $0.0001 per share exercise price of each pre-funded warrant. The gross proceeds from the offering are expected to be approximately...

Opportunistic capital raise for general corporate purposes Either net proceeds from this offering or cash on hand to be used to purchase cash-settled capped calls to offset economic dilution up to a cap of 125% premium to the last reported sale price of Bitfarms’ common shares on Nasdaq on the date of pricingTORONTO, Ontario and NEW YORK, Oct. 16, 2025 (GLOBE NEWSWIRE) — Bitfarms Ltd. (NASDAQ/TSX: BITF), a North American energy and digital infrastructure company (“Bitfarms” or the “Company”), today announced that it has priced its offering of US$500 million aggregate principal amount of 1.375% convertible senior notes due 2031 (the “Convertible Notes”). Bitfarms has also granted the initial purchasers of the Convertible Notes an option to purchase, for a 13-day period beginning on and including the date on which the Convertible...

SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) — Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced that the investigational new drug (“IND”) application for an open-label, two-arm, randomized, active-controlled, phase 2/3 clinical study comparing the company’s product, recombinant humanized anti-PD-1/VEGF bispecific antibody (code: JS207), to nivolumab for the neoadjuvant treatment of patients with stage Ⅱ/Ⅲ, resectable, actionable genomic aberration (AGA)-negative, non-small cell lung cancer (“NSCLC”) has been approved by the U.S. Food and Drug Administration (the “FDA”). Lung cancer is currently a malignant tumor with the highest prevalence and mortality...

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted a non-transferrable voucher for daraxonrasib (RMC-6236), the company’s RAS(ON) multi-selective inhibitor, under the Commissioner’s National Priority Voucher (CNPV) pilot program. Daraxonrasib is being studied in two global Phase 3 clinical trials, RASolute 302 in patients with previously treated metastatic pancreatic ductal adenocarcinoma and RASolve 301 in patients with previously treated metastatic non-small cell lung cancer. “We are honored to receive one of the first vouchers awarded under the Commissioner’s National Priority Voucher...